Navigation Links
NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

Inflammation, along with high blood pressure and high cholesterol, plays a major role in heart attack and stroke. The Cardiovascular Inflammation Reduction Trial (CIRT) will determine whether treatment with a drug specifically targeting inflammation reduces rates of cardiovascular events among adults who have had a heart attack within the past five years and who also have type 2 diabetes or metabolic syndrome. The trial will randomly assign participants to receive methotrexate given at 10 to 20 milligrams weekly for three to four years or a placebo. Methotrexate is an inexpensive generic drug commonly used at low doses to treat rheumatoid arthritis. It is also used at higher doses to treat certain forms of cancers such as leukemias and lymphomas.

"This trial could have global impact by potentially changing treatment recommendations for millions of individuals with heart disease," said Gary H. Gibbons, M.D., director of the NHLBI.

Each year, over 2 million people in the United States have heart attacks or strokes, and many of them die. "If this generic drug, which is already on the market at low cost, proves effective for reducing risk of heart attacks, stroke, or death, it has the potential for broad public health impact in saving lives and reducing disease," said Paul Ridker, M.D., M.P.H., an expert in inflammation biology as it relates to heart attack and stroke. Dr. Ridker, who will serve as principal investigator for CIRT, is the Eugene Braunwald Professor of Medicine at Harvard Medical School, and director of the Center for Cardiovascular Disease Prevention at the Brigham and Women's Hospital, Boston.

Adults who have type 2 diabetes are much more likely to die of heart disease or stroke than people without type 2 diabetes. Metabolic syndromea cluster of traits that includes a large waistline, high blood pressure, high levels of blood triglyceride (a type of fat), high blood sugar, and low blood HDL (the good cholesterol)also raises the risk of heart attack and stroke. Many people with type 2 diabetes and obesity also have metabolic syndrome. People with diabetes or metabolic syndrome typically have elevated blood levels of various markers of inflammation.

CIRT will enroll 7,000 patients at 350-400 sites across the United States and Canada over the next 2.5 years and will follow them for two to four years (average 2.5 years). Site selection will begin in November 2012, and patient recruitment will start in March 2013.

Eligible participants who tolerate the drug without side effects over a five-week test period will be randomly assigned to receive standard care plus placebo or standard care plus low-dose methotrexate. Participants will also take folic acid, which is routinely given with methotrexate to prevent vitamin deficiencies.

In addition to measuring the number of strokes, heart attacks, and heart-related deaths among participants, CIRT will determine if low-dose methotrexate reduces death from all causes and certain heart- and blood vessel-related conditions and events, including incident deep vein thrombosis, pulmonary embolism, atrial fibrillation, hospitalization for chest pain or congestive heart failure, non-surgical procedures or coronary artery bypass surgery, and newly diagnosed type 2 diabetes. CIRT will also establish a blood and DNA bank to study the effect of low-dose methotrexate on a number of inflammatory biomarkers.


Contact: NHLBI
NIH/National Heart, Lung and Blood Institute

Related medicine news :

1. Dallas Launches Insecticide Spraying Against West Nile Virus
2. Elsevier launches new journal: Performance Enhancement & Health
3. American Chemical Society launches 2012 edition of popular Prized Science video series
4. ASH launches multi-million-dollar grant program to support critical blood disease research
5. Oxford University Press launches Evolution, Medicine, and Public Health
6. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
7. LaStone Launches Merger with TIR Massage Stone To Further The Advancement of Massage Therapy Education in 2012
8. Washington Massage School Launches Private Practice Clinic
9. beyondblue Launches Depression & Anxiety website and Info Line for Men
10. Amirsys AnatomyOne Launches Today
11. Friends Life Care, a Pennsylvania Based Long-Term Care Provider, Launches VigR eMeetinghouse — An Interactive Online Community
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... ... 19, 2015, high school aged female athletes, particularly in the area of track ... motion and mechanical overuse injuries than male peers in the same age group. ...
(Date:10/12/2015)... AL (PRWEB) , ... October 12, 2015 , ... American ... continues to expand its footprint by opening its 151st medical center. Located at 606A ... , “We’re excited to continue fulfilling our mission of making quality health care ...
(Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc . is ... Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, and hospitals ... process. In addition, the DSM is also being offered to healthcare media organizations to ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group is proud ... contact channel benchmarking study. Be a part of this insightful and leading-edge ... customer experience, customer journey, contact channel execution and intelligence, workforce optimization, and tools ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... For the ... year earning the highest distinction with its first Platinum Award. , The Bizrate ... status, but also earned a score of at least 9.0 or above out of ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Okla. , Oct. 12, 2015  Millions of ... free from the shackles of tobacco. An April ... at Kings College London showed electronic cigarettes to be ... smoking. But more than a decade after the technology ... it remained unchanged.    --> ...
(Date:10/12/2015)... , Oct. 12, 2015 ... improve and enhance the quality of images produced ... substances (contrast media) used in magnetic resonance imaging, ... These devices allow the radiologists to interpret the ... conditions of the body. Contrast media can be ...
(Date:10/12/2015)... -- In a Sutter Institute of Medical Research study published ... Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was ... patients in the early, pre-dementia phase of Alzheimer,s disease. ... extracted from the plasma of more than 1,000 blood ... found in patients with Alzheimer,s disease. Sutter Institute of ...
Breaking Medicine Technology: